239 related articles for article (PubMed ID: 12459020)
1. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound.
Kratz F; Warnecke A; Scheuermann K; Stockmar C; Schwab J; Lazar P; Drückes P; Esser N; Drevs J; Rognan D; Bissantz C; Hinderling C; Folkers G; Fichtner I; Unger C
J Med Chem; 2002 Dec; 45(25):5523-33. PubMed ID: 12459020
[TBL] [Abstract][Full Text] [Related]
2. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy.
Kratz F; Müller-Driver R; Hofmann I; Drevs J; Unger C
J Med Chem; 2000 Apr; 43(7):1253-6. PubMed ID: 10753462
[No Abstract] [Full Text] [Related]
3. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
4. Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells of doxorubicin and an albumin-binding prodrug of doxorubicin.
Abu Ajaj K; Graeser R; Kratz F
Breast Cancer Res Treat; 2012 Jul; 134(1):117-29. PubMed ID: 22228402
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of an albumin-binding prodrug of doxorubicin that is cleaved by prostate-specific antigen (PSA) in a PSA-positive orthotopic prostate carcinoma model (LNCaP).
Graeser R; Chung DE; Esser N; Moor S; Schächtele C; Unger C; Kratz F
Int J Cancer; 2008 Mar; 122(5):1145-54. PubMed ID: 17973264
[TBL] [Abstract][Full Text] [Related]
6. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen.
Kratz F; Mansour A; Soltau J; Warnecke A; Fichtner I; Unger C; Drevs J
Arch Pharm (Weinheim); 2005 Oct; 338(10):462-72. PubMed ID: 16211657
[TBL] [Abstract][Full Text] [Related]
7. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
Kratz F; Ehling G; Kauffmann HM; Unger C
Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
[TBL] [Abstract][Full Text] [Related]
8. Maleimide-oligo(ethylene glycol) derivatives of camptothecin as albumin-binding prodrugs: synthesis and antitumor efficacy.
Warnecke A; Kratz F
Bioconjug Chem; 2003; 14(2):377-87. PubMed ID: 12643748
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
Kratz F; Azab S; Zeisig R; Fichtner I; Warnecke A
Int J Pharm; 2013 Jan; 441(1-2):499-506. PubMed ID: 23149257
[TBL] [Abstract][Full Text] [Related]
10. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials.
Kratz F
Expert Opin Investig Drugs; 2007 Jun; 16(6):855-66. PubMed ID: 17501697
[TBL] [Abstract][Full Text] [Related]
11. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo study of an albumin-binding prodrug of doxorubicin that is cleaved by cathepsin B.
Abu Ajaj K; Graeser R; Fichtner I; Kratz F
Cancer Chemother Pharmacol; 2009 Jul; 64(2):413-8. PubMed ID: 19229536
[TBL] [Abstract][Full Text] [Related]
13. Development of dual-acting prodrugs for circumventing multidrug resistance.
Abu Ajaj K; Kratz F
Bioorg Med Chem Lett; 2009 Feb; 19(3):995-1000. PubMed ID: 19131246
[TBL] [Abstract][Full Text] [Related]
14. Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.
Pes L; Koester SD; Magnusson JP; Chercheja S; Medda F; Abu Ajaj K; Rognan D; Daum S; Nollmann FI; Garcia Fernandez J; Perez Galan P; Walter HK; Warnecke A; Kratz F
J Control Release; 2019 Feb; 296():81-92. PubMed ID: 30639692
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.
Warnecke A; Fichtner I; Sass G; Kratz F
Arch Pharm (Weinheim); 2007 Aug; 340(8):389-95. PubMed ID: 17628030
[TBL] [Abstract][Full Text] [Related]
16. Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates.
Kratz F; Drevs J; Bing G; Stockmar C; Scheuermann K; Lazar P; Unger C
Bioorg Med Chem Lett; 2001 Aug; 11(15):2001-6. PubMed ID: 11454467
[TBL] [Abstract][Full Text] [Related]
17. Preparation, characterization and in vitro efficacy of albumin conjugates of doxorubicin.
Kratz F; Beyer U; Collery P; Lechenault F; Cazabat A; Schumacher P; Falken U; Unger C
Biol Pharm Bull; 1998 Jan; 21(1):56-61. PubMed ID: 9477169
[TBL] [Abstract][Full Text] [Related]
18. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
[TBL] [Abstract][Full Text] [Related]
19. In vivo evaluation of a novel albumin-binding prodrug of doxorubicin in an orthotopic mouse model of prostate cancer (LNCaP).
Elsadek B; Graeser R; Esser N; Schäfer-Obodozie C; Tsurumi C; Abu Ajaj K; Warnecke A; Unger C; Saleem T; Kratz F
Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):14-21. PubMed ID: 21042336
[TBL] [Abstract][Full Text] [Related]
20. Development of protein-binding bifunctional linkers for a new generation of dual-acting prodrugs.
Abu Ajaj K; Biniossek ML; Kratz F
Bioconjug Chem; 2009 Feb; 20(2):390-6. PubMed ID: 19199576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
